Downloads
Download
温胆汤类方干预肥胖的网络化调控机制研究探讨（二）. (2026). 环球医学研究, 3(5), 88-93. https://doi.org/10.62836/medicine.v3i5.1516
Copyright (c) 2026 马嘉言, 周瑞莲, 王亦釤, 杨阳
This work is licensed under a Creative Commons Attribution 4.0 International License.
温胆汤类方干预肥胖的网络化调控机制研究探讨（二）
马嘉言1，周瑞莲1，王亦釤1，杨阳1,2*
1.河北中医药大学，河北石家庄050200；
2.河北省心脑血管病中医药防治研究重点实验室，河北石家庄050091
摘要：肥胖伴随胰岛素、瘦素及炎症因子等信号转导受阻，并伴脂肪细胞自噬异常与焦亡过度激活。温胆汤为经典治痰名方，本文归纳温胆汤类方对分子信号通路及下游效应机制的调控作用：其可激活PPARs、AMPK、PI3K/Akt等能量代谢通路，抑制NF-κB、MAPK、JAK2/STAT3等炎症通路，减轻中枢瘦素抵抗与慢性炎症；并抑制脂肪细胞过度自噬及NLRP3/Caspase-1/GSDMD介导的经典焦亡途径，减轻炎症与氧化应激，呈现“多通路-多靶点-多环节”的网络化调控模式。
参考文献
[1] 徐佳玲,袁可望,刘彩玲,等.基于网络药理学及分子对接技术探究温胆汤治疗肥胖痰湿证的作用机制[J].江西中医药,2024,55(11):47-55.
[2] Hou X, Chen Y, Dong W, Li X, Ji S. The context-dependent roles of PPAR-γ in adipocyte differentiation and obesity: a master regulator with dual functions[J]. Front Nutr. 2026, 13: 1820776.
[3] 张一恒,皇苏州,陆星星,等.温胆汤治疗NAFLD的物质基础及作用机制研究[J/OL].南京中医药大学学报,2026,(4):551-564.
[4] 喻松仁,徐佳玲,刘志勇,等.基于胰岛巨噬细胞M1极化探讨温胆汤对肥胖痰湿证炎症状态的影响[J].中华中医药学刊,2026,44(5):1-6+259-263.
[5] Liu ZC, Fu HJ, Li NC, Deng FJ, Gan YK, Ye YJ, Huang BH, Liu C, Chen JH, Li XF. Systematic pharmacology and experimental validation to elucidate the inflammation-associated mechanism of Huanglian Wendan (HLWD) decoction in the treatment of MAFLD associated with atherosclerosis[J]. J Ethnopharmacol. 2025, 337(Pt 1): 118841.
[6] Steinberg GR, Hardie DG. New insights into activation and function of the AMPK[J]. Nat Rev Mol Cell Biol. 2023, 24(4): 255-272.
[7] 姚凤云,王非云,刘超,等.加味温胆汤对雄性营养性肥胖大鼠INS/AMPK-ACC通路的影响[J].时珍国医国药,2020,31(5):1051-1052.
[8] 姚凤云,刘超,王炳志,等.加味温胆汤对雌性营养性肥胖大鼠AMPK的影响[J].中华中医药杂志,2020,35(9):4363-4366.
[9] 刘超,左铮云,王炳志,等.加味温胆汤对雌性营养性肥胖大鼠LEP,ACC和MCA的影响[J].中国实验方剂学杂志,2020,26(1):87-91.
[10] 李永鑫,崔言坤,王琳,等.加味温胆汤改善肥胖T2DM模型大鼠糖脂代谢紊乱的机制研究[J].时珍国医国药,2024,35(9):2126-2129.
[11] Zhu J, Chen Y, Han Y, Li J. Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway[J]. PLoS One. 2025, 20(9): e0331303.
[12] 刘莉,王雪梅,邹国良,等.黄连温胆汤对代谢综合征大鼠胰岛素抵抗、糖脂代谢及GLUT-4的影响[J].辽宁中医杂志,2021,48(12):190-193.
[13] 樊德慧,韩宇博,邹国良,等.黄连温胆汤对胰岛素抵抗大鼠肝脏脂质蓄积的影响[J].中国中医药信息杂志,2022,29(3):59-64.
[14] Savova MS, Mihaylova LV, Tews D, Wabitsch M, Georgiev MI. Targeting PI3K/AKT signaling pathway in obesity[J]. Biomed Pharmacother. 2023, 159: 114244.
[15] 喻松仁,刘彩玲,钟友宝,等.温胆汤对肥胖痰湿证大鼠糖脂代谢及PI3K/Akt信号通路的影响[J].中华中医药杂志,2024,39(10):5468-5473.
[16] 喻松仁,刘彩玲,周丽,等.温胆汤通过调控PI3K/Akt/mTOR通路介导的脂肪细胞自噬对肥胖痰湿证炎症状态的影响[J].中国实验方剂学杂志,2023,29(14):1-10.
[17] 姚凤云,张蓉,左铮云,等.加味温胆汤调控INSR/PI3K/Akt/GLUT4信号通路抗雄性幼鼠营养性肥胖机制研究[J].中华中医药学刊,2021,39(9):1-4.
[18] 张凯茵,姚凤云,韩瑶瑶,等.加味温胆汤对3T3-L1脂肪细胞糖脂代谢及PI3K/Akt/FOXO1信号通路的影响[J].中成药,2025,47(10):3242-3248.
[19] 姚凤云,韩瑶瑶,张凯茵,等.基于PI3K/AKT-GLUT4通路探讨加味温胆汤改善肥胖型2型糖尿病大鼠胰岛素抵抗的作用[J].中华中医药学刊,2026.
[20] Petrascu FM, Matei SC, Olteanu GE, Barna R, Marian C. Canonical NF-κB Pathway as a Central Regulator of Obesity-Associated Inflammation: A Narrative Review[J]. Biomedicines. 2025, 13(12): 3050.
[21] 林黄果,钟胜,蔡鑫桂,等.温胆汤对代谢综合征大鼠炎症介质表达的影响[J].广州中医药大学学报,2018,35(4):664-668.
[22] 彭伟航,张为章,黄小燕,等.疏肝温胆汤对代谢综合征小鼠胰岛素抵抗及肝脏脂质沉积的影响及机制[J].中药新药与临床药理,2025,36(8):1243-1248.
[23] 罗思聪,蔡海荣,蔡鑫桂,等.疏肝温胆汤对代谢综合征大鼠TLR4/IKKβ/NF-κB通路的影响[J].时珍国医国药,2023,34(12):2848-2851.
[24] 刘莉,邓晓威,金娟.黄连温胆汤对代谢综合征大鼠核转录因子及肿瘤坏死因子的影响[J].中医药信息,2012,29(4):67-70.
[25] 刘莉,许锋锐,芦晔.黄连温胆汤加减对代谢综合征大鼠肿瘤坏死因子-α和白介素-6的影响[J].湖北中医药大学学报,2012,14(3):11-13.
[26] Ng GYQ, Loh ZW, Fann DY, Mallilankaraman K, Arumugam TV, Hande MP. Role of Mitogen-Activated Protein (MAP) Kinase Pathways in Metabolic Diseases[J]. Genome Integr. 2024, 15: e20230003.
[27] 彭坤明,包君丽,高欣元,等.黄连温胆汤对慢性间歇性低氧代谢综合征大鼠p38MAPK/NF-κB信号通路的影响[J].医师在线,2023,13(2):14-18.
[28] Collotta D, Franchina MP, Carlucci V, Collino M. Recent advances in JAK inhibitors for the treatment of metabolic syndrome[J]. Front Pharmacol. 2023, 14: 1245535.
[29] 周增丁,李小林,巫国辉.JAK/STATs通路与肥胖发病机制的研究进展[J].中国美容医学,2009,18(2):271-274.
[30] 喻松仁,白洋,王河宝,等.温胆汤对肥胖大鼠血清瘦素及下丘脑STAT3和SOCS3表达的影响[J].中医杂志,2019,60(3):232-236.
[31] 喻松仁,舒晴,白洋,等.温胆汤对肥胖痰湿证大鼠相关炎症因子及JAK2/STAT3通路关键分子STAT3表达的影响[J].中国实验方剂学杂志,2019,25(6):39-44.
[32] 杨星,郑承红,范彦博,等.基于JAK2/STAT3信号通路探讨加味黄连温胆汤调控自噬改善HepG2细胞胰岛素抵抗的作用机制[J].中国中医药信息杂志,2025,32(8):114-121.
[33] 马伯艳,辛相如,陆阁玲,等.基于NLRP3/Caspase-1信号通路探讨黄连温胆汤改善HepG2细胞胰岛素抵抗的作用机制[J].中国实验方剂学杂志,2022,28(18):1-11.
[34] 武姗姗,张御乐,杨越,等.基于NLRP3介导的神经炎症和瘦素抵抗探讨黄连温胆汤改善奥氮平诱导的小鼠摄食失衡的机制[J].中国中药杂志,2025,50(24):6901-6909.
[35] Ye B, Zhou Y, Wang Y, Shi Q, Huang S, Yang H, Mao B, Wang P. Chaihu-Wendan Decoction alleviates obesity through PTEN-mediated uncoupling of metabolic signaling and macrophage activation. Front Endocrinol (Lausanne). 2026, 17: 1779657.
[36] Jiang M, Wu Q, Yu R, Zhang Z, Wen G, Zhong Y, Tan Z, Li Z, Xie X. Integrating UHPLC-Q-TOF/MS and multi-omics to elucidate the regulatory mechanisms of Xiong’s Shiwei Wendan decoction in MASLD. J Chromatogr B Analyt Technol Biomed Life Sci. 2026, 1281: 125181.
[37] Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues[J]. Cell. 2011, 147(4): 728-41.
[38] Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death[J]. Trends Biochem Sci. 2017, 42(4): 245-254.
[39] 李寒,王宁,马伯艳.基于肝细胞焦亡的黄连温胆汤干预IGTIR的机制[J].中国中药杂志,2021,46(13):3394-3401.
[40] 田旭升,李云凤,李寒,等.黄连温胆汤对IGT大鼠骨骼肌细胞焦亡经典通路的影响[J].中国实验方剂学杂志,2021,27(18):1-8.
[41] Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders[J]. Nature. 2017, 542(7640): 177-185.
[42] 姚凤云,刘春花,刘成,等.加味温胆汤抗大鼠营养性肥胖的机制探讨[J].中国实验方剂学杂志,2013,19(19):280-282.
[43] 田苗,马伯艳,张贺,等.化瘀温胆汤对糖耐量低减大鼠肝细胞线粒体SOD及MDA水平的影响[J].中医药学报,2018,46(2):33-35.
[44] Chen M, Yang F, Yang X, Lai X, Gao Y. Systematic Understanding of Mechanisms of a Chinese Herbal Formula in Treatment of Metabolic Syndrome by an Integrated Pharmacology Approach. Int J Mol Sci. 2016, 17(12): 2114.
[45] Chen M, Yang F, Kang J, Gan H, Lai X, Gao Y. Discovery of molecular mechanism of a clinical herbal formula upregulating serum HDL-c levels in treatment of metabolic syndrome by in vivo and computational studies. Bioorg Med Chem Lett. 2018, 28(2): 174-180.
[46] Xu N, Ijaz M, Shu Y, Wang P, Ma L, Wang P, Ding H, Shahbaz M, Shi H. The in vivo study on antioxidant activity of wendan decoction in treating hyperlipidemia: a pharmacokinetic-pharmacodynamic (PK-PD) model. Front Pharmacol. 2024, 15: 1260603.
[47] 彭鹏,韩宇博,娄宏君,等.黄连温胆汤含药血清对胰岛素抵抗脂肪细胞改善作用的蛋白质组学研究[J].海南医学院学报,2019,25(8):566-571.
[2] Hou X, Chen Y, Dong W, Li X, Ji S. The context-dependent roles of PPAR-γ in adipocyte differentiation and obesity: a master regulator with dual functions[J]. Front Nutr. 2026, 13: 1820776.
[3] 张一恒,皇苏州,陆星星,等.温胆汤治疗NAFLD的物质基础及作用机制研究[J/OL].南京中医药大学学报,2026,(4):551-564.
[4] 喻松仁,徐佳玲,刘志勇,等.基于胰岛巨噬细胞M1极化探讨温胆汤对肥胖痰湿证炎症状态的影响[J].中华中医药学刊,2026,44(5):1-6+259-263.
[5] Liu ZC, Fu HJ, Li NC, Deng FJ, Gan YK, Ye YJ, Huang BH, Liu C, Chen JH, Li XF. Systematic pharmacology and experimental validation to elucidate the inflammation-associated mechanism of Huanglian Wendan (HLWD) decoction in the treatment of MAFLD associated with atherosclerosis[J]. J Ethnopharmacol. 2025, 337(Pt 1): 118841.
[6] Steinberg GR, Hardie DG. New insights into activation and function of the AMPK[J]. Nat Rev Mol Cell Biol. 2023, 24(4): 255-272.
[7] 姚凤云,王非云,刘超,等.加味温胆汤对雄性营养性肥胖大鼠INS/AMPK-ACC通路的影响[J].时珍国医国药,2020,31(5):1051-1052.
[8] 姚凤云,刘超,王炳志,等.加味温胆汤对雌性营养性肥胖大鼠AMPK的影响[J].中华中医药杂志,2020,35(9):4363-4366.
[9] 刘超,左铮云,王炳志,等.加味温胆汤对雌性营养性肥胖大鼠LEP,ACC和MCA的影响[J].中国实验方剂学杂志,2020,26(1):87-91.
[10] 李永鑫,崔言坤,王琳,等.加味温胆汤改善肥胖T2DM模型大鼠糖脂代谢紊乱的机制研究[J].时珍国医国药,2024,35(9):2126-2129.
[11] Zhu J, Chen Y, Han Y, Li J. Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway[J]. PLoS One. 2025, 20(9): e0331303.
[12] 刘莉,王雪梅,邹国良,等.黄连温胆汤对代谢综合征大鼠胰岛素抵抗、糖脂代谢及GLUT-4的影响[J].辽宁中医杂志,2021,48(12):190-193.
[13] 樊德慧,韩宇博,邹国良,等.黄连温胆汤对胰岛素抵抗大鼠肝脏脂质蓄积的影响[J].中国中医药信息杂志,2022,29(3):59-64.
[14] Savova MS, Mihaylova LV, Tews D, Wabitsch M, Georgiev MI. Targeting PI3K/AKT signaling pathway in obesity[J]. Biomed Pharmacother. 2023, 159: 114244.
[15] 喻松仁,刘彩玲,钟友宝,等.温胆汤对肥胖痰湿证大鼠糖脂代谢及PI3K/Akt信号通路的影响[J].中华中医药杂志,2024,39(10):5468-5473.
[16] 喻松仁,刘彩玲,周丽,等.温胆汤通过调控PI3K/Akt/mTOR通路介导的脂肪细胞自噬对肥胖痰湿证炎症状态的影响[J].中国实验方剂学杂志,2023,29(14):1-10.
[17] 姚凤云,张蓉,左铮云,等.加味温胆汤调控INSR/PI3K/Akt/GLUT4信号通路抗雄性幼鼠营养性肥胖机制研究[J].中华中医药学刊,2021,39(9):1-4.
[18] 张凯茵,姚凤云,韩瑶瑶,等.加味温胆汤对3T3-L1脂肪细胞糖脂代谢及PI3K/Akt/FOXO1信号通路的影响[J].中成药,2025,47(10):3242-3248.
[19] 姚凤云,韩瑶瑶,张凯茵,等.基于PI3K/AKT-GLUT4通路探讨加味温胆汤改善肥胖型2型糖尿病大鼠胰岛素抵抗的作用[J].中华中医药学刊,2026.
[20] Petrascu FM, Matei SC, Olteanu GE, Barna R, Marian C. Canonical NF-κB Pathway as a Central Regulator of Obesity-Associated Inflammation: A Narrative Review[J]. Biomedicines. 2025, 13(12): 3050.
[21] 林黄果,钟胜,蔡鑫桂,等.温胆汤对代谢综合征大鼠炎症介质表达的影响[J].广州中医药大学学报,2018,35(4):664-668.
[22] 彭伟航,张为章,黄小燕,等.疏肝温胆汤对代谢综合征小鼠胰岛素抵抗及肝脏脂质沉积的影响及机制[J].中药新药与临床药理,2025,36(8):1243-1248.
[23] 罗思聪,蔡海荣,蔡鑫桂,等.疏肝温胆汤对代谢综合征大鼠TLR4/IKKβ/NF-κB通路的影响[J].时珍国医国药,2023,34(12):2848-2851.
[24] 刘莉,邓晓威,金娟.黄连温胆汤对代谢综合征大鼠核转录因子及肿瘤坏死因子的影响[J].中医药信息,2012,29(4):67-70.
[25] 刘莉,许锋锐,芦晔.黄连温胆汤加减对代谢综合征大鼠肿瘤坏死因子-α和白介素-6的影响[J].湖北中医药大学学报,2012,14(3):11-13.
[26] Ng GYQ, Loh ZW, Fann DY, Mallilankaraman K, Arumugam TV, Hande MP. Role of Mitogen-Activated Protein (MAP) Kinase Pathways in Metabolic Diseases[J]. Genome Integr. 2024, 15: e20230003.
[27] 彭坤明,包君丽,高欣元,等.黄连温胆汤对慢性间歇性低氧代谢综合征大鼠p38MAPK/NF-κB信号通路的影响[J].医师在线,2023,13(2):14-18.
[28] Collotta D, Franchina MP, Carlucci V, Collino M. Recent advances in JAK inhibitors for the treatment of metabolic syndrome[J]. Front Pharmacol. 2023, 14: 1245535.
[29] 周增丁,李小林,巫国辉.JAK/STATs通路与肥胖发病机制的研究进展[J].中国美容医学,2009,18(2):271-274.
[30] 喻松仁,白洋,王河宝,等.温胆汤对肥胖大鼠血清瘦素及下丘脑STAT3和SOCS3表达的影响[J].中医杂志,2019,60(3):232-236.
[31] 喻松仁,舒晴,白洋,等.温胆汤对肥胖痰湿证大鼠相关炎症因子及JAK2/STAT3通路关键分子STAT3表达的影响[J].中国实验方剂学杂志,2019,25(6):39-44.
[32] 杨星,郑承红,范彦博,等.基于JAK2/STAT3信号通路探讨加味黄连温胆汤调控自噬改善HepG2细胞胰岛素抵抗的作用机制[J].中国中医药信息杂志,2025,32(8):114-121.
[33] 马伯艳,辛相如,陆阁玲,等.基于NLRP3/Caspase-1信号通路探讨黄连温胆汤改善HepG2细胞胰岛素抵抗的作用机制[J].中国实验方剂学杂志,2022,28(18):1-11.
[34] 武姗姗,张御乐,杨越,等.基于NLRP3介导的神经炎症和瘦素抵抗探讨黄连温胆汤改善奥氮平诱导的小鼠摄食失衡的机制[J].中国中药杂志,2025,50(24):6901-6909.
[35] Ye B, Zhou Y, Wang Y, Shi Q, Huang S, Yang H, Mao B, Wang P. Chaihu-Wendan Decoction alleviates obesity through PTEN-mediated uncoupling of metabolic signaling and macrophage activation. Front Endocrinol (Lausanne). 2026, 17: 1779657.
[36] Jiang M, Wu Q, Yu R, Zhang Z, Wen G, Zhong Y, Tan Z, Li Z, Xie X. Integrating UHPLC-Q-TOF/MS and multi-omics to elucidate the regulatory mechanisms of Xiong’s Shiwei Wendan decoction in MASLD. J Chromatogr B Analyt Technol Biomed Life Sci. 2026, 1281: 125181.
[37] Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues[J]. Cell. 2011, 147(4): 728-41.
[38] Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death[J]. Trends Biochem Sci. 2017, 42(4): 245-254.
[39] 李寒,王宁,马伯艳.基于肝细胞焦亡的黄连温胆汤干预IGTIR的机制[J].中国中药杂志,2021,46(13):3394-3401.
[40] 田旭升,李云凤,李寒,等.黄连温胆汤对IGT大鼠骨骼肌细胞焦亡经典通路的影响[J].中国实验方剂学杂志,2021,27(18):1-8.
[41] Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders[J]. Nature. 2017, 542(7640): 177-185.
[42] 姚凤云,刘春花,刘成,等.加味温胆汤抗大鼠营养性肥胖的机制探讨[J].中国实验方剂学杂志,2013,19(19):280-282.
[43] 田苗,马伯艳,张贺,等.化瘀温胆汤对糖耐量低减大鼠肝细胞线粒体SOD及MDA水平的影响[J].中医药学报,2018,46(2):33-35.
[44] Chen M, Yang F, Yang X, Lai X, Gao Y. Systematic Understanding of Mechanisms of a Chinese Herbal Formula in Treatment of Metabolic Syndrome by an Integrated Pharmacology Approach. Int J Mol Sci. 2016, 17(12): 2114.
[45] Chen M, Yang F, Kang J, Gan H, Lai X, Gao Y. Discovery of molecular mechanism of a clinical herbal formula upregulating serum HDL-c levels in treatment of metabolic syndrome by in vivo and computational studies. Bioorg Med Chem Lett. 2018, 28(2): 174-180.
[46] Xu N, Ijaz M, Shu Y, Wang P, Ma L, Wang P, Ding H, Shahbaz M, Shi H. The in vivo study on antioxidant activity of wendan decoction in treating hyperlipidemia: a pharmacokinetic-pharmacodynamic (PK-PD) model. Front Pharmacol. 2024, 15: 1260603.
[47] 彭鹏,韩宇博,娄宏君,等.黄连温胆汤含药血清对胰岛素抵抗脂肪细胞改善作用的蛋白质组学研究[J].海南医学院学报,2019,25(8):566-571.